The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. - Wikidata - awgldk - TriplyDB

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

http://www.wikidata.org/entity/Q39508981

about

Micelle-like nanoparticles as carriers for DNA and siRNA Progress toward in vivo use of siRNAs-II Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.Silencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats.Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles.Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for real-time RT-PCR in gene silencing.Amplification and re-generation of LNA-modified libraries.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice.High-density lipoprotein facilitates in vivo delivery of α-tocopherol-conjugated short-interfering RNA to the brain.Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer.Synthesis, biocompatible, and self-assembly properties of poly (ethylene glycol)/lactobionic acid-grafted chitosan.Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels LNA-based oligonucleotide electrotransfer for miRNA inhibition.Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo Nano-enabled delivery of diverse payloads across complex biological barriers.Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles.Pharmacokinetic Behaviors of Intravenously Administered siRNA in Glandular Tissues.Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.Linear polyethylenimine produced by partial acid hydrolysis of poly(2-ethyl-2-oxazoline) for DNA and siRNA delivery in vitro.Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-α siRNA in Chronic Inflammation Sites.Adsorption and release of siRNA from porous silica.Clinical developments in nanotechnology for cancer therapy.Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis.Recent advances of siRNA delivery by nanoparticles.RNAi-based therapeutic strategies for metabolic disease.RNA interference for performance enhancement and detection in doping control.Action and reaction: the biological response to siRNA and its delivery vehicles.Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.Delivery of RNAi therapeutics: work in progress.

P2860

Q27001558-FB15FDBA-691D-4B55-A0E2-1529DA0995E3 Q28255877-64144121-35F1-49DB-8A2A-1487F919CFAD Q30385729-8102D8FB-5C84-46CA-BC0E-FEA43F9FACDF Q33626606-2D1914B6-C352-40E1-85AC-B7CADBDDFB5C Q33635355-4DBEC774-16BB-4582-94EA-59F14DD57B32 Q33902729-A07FFE13-038B-4A72-95CB-94277E485295 Q34080235-51CD70D9-B0D5-4B3D-BA12-428C1AA614D4 Q34177543-5FA23FCA-E430-4947-B753-C73BB60EF8A3 Q34467738-8D5E64E6-807E-4182-9733-996EA24B31F1 Q34622662-B0E1193A-7CDC-49D2-A4CA-C18C1F00C45F Q34785218-E383E1AB-9258-49D2-9465-E0D11610DF34 Q35070066-3C2289D2-9F82-46CB-9652-1C09AE580212 Q35117351-0FCBA36E-E5CD-4713-9E97-44C67438D79C Q35171893-88843EBD-BCE5-4D7C-A542-1585C34B5130 Q35230177-7C99C669-A688-40E8-B451-182CAD48A6AD Q35681765-FDB4BFB6-71FE-4793-90BF-E2A0306D81F4 Q35764362-98223AEE-C002-42A7-9695-C9DC1B967624 Q35778918-C66FE2C4-20E0-45A6-BCA7-FDA60DA471A1 Q35846845-5228F41F-B140-4A14-9DA1-5E2ED0492AE5 Q35846848-58E5B901-32CC-4068-9D81-E8F66C02E2E2 Q36142470-0A2B8E6E-E510-4B49-8F0E-321E8C5D908A Q36174842-D0C0E5CB-7158-4FC8-82FA-1053B304E689 Q36299367-980E9DF1-8F78-456D-9680-BC3B9DD97936 Q36307467-10B4D854-C25C-43E7-8513-D610B673644F Q36331202-240EAB7D-B0A9-45BB-987A-12D06798C4E4 Q36906374-475817F4-D54C-4DE4-9F13-4A330181C1D2 Q37112951-0AC98F59-EA51-4858-9905-596DFC983B72 Q37171319-76856CAE-71A8-48FE-BD26-B21E2F0D03E3 Q37278628-B1AA824B-BFD4-4F65-A8CA-401D30DFDAE0 Q37672324-B659B24E-67C6-4698-8B6C-A8461A49C423 Q37719870-94678CF7-1EBC-4C5C-90B3-F33885449A21 Q37765187-91BDD6F2-0005-43B3-B5A3-65E8F777624C Q37793079-6C0FC4BA-5C3B-4B9D-A6F9-8225AA469A0D Q37807993-F3AABF8D-5B4B-4725-A46D-ABE075465371 Q37854061-2EE24BCA-4B9A-4D78-95C0-A35EEBBE6A9E Q37866632-0A8D6E43-404A-49E5-8409-8CB3BCFE168B Q37949928-BC18C024-F8A9-4FEB-83C2-1817E0F2EA46 Q37976576-5F5A1656-FC1C-4628-A9A7-751BD85F9E19 Q38090525-FDB86F7F-05D6-46A1-B2E8-7346993D4084 Q38160246-80B3736F-FF7D-408F-BE95-7F05E63224B4

P2860

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

http://www.wikidata.org/entity/Q39508981

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

The effect of chemical modific ...... distribution of siRNA in mice.

@en

The effect of chemical modific ...... distribution of siRNA in mice.

@nl

type

label

The effect of chemical modific ...... distribution of siRNA in mice.

@en

The effect of chemical modific ...... distribution of siRNA in mice.

@nl

prefLabel

The effect of chemical modific ...... distribution of siRNA in mice.

@en

The effect of chemical modific ...... distribution of siRNA in mice.

@nl

P1433

Q39508981-7D78AFD8-CC84-491F-B7ED-72987E53D697

P1476

Q39508981-A01D304C-C88D-4487-9906-897127DE5838

P2093

Q39508981-3F60E2DD-2582-4F91-B1C2-B450D5E9D37E

Q39508981-758F03AE-FF8F-41CA-9373-990CB21C5852

Q39508981-7C6374C2-BE04-402C-81BA-B145C691EF0F

Q39508981-D90647C2-92FD-4FAA-8585-7E1532765408

Q39508981-E4B187DD-EA5A-4C25-AA10-F7E44330DB6B

P2860

Q39508981-02383C41-A973-4F20-9ED7-C3F2B0016497

Q39508981-0D471E64-88D7-416D-A2F2-7874F3A34C9A

Q39508981-11AD7C69-9D52-47F0-9EB2-C040F5662D99

Q39508981-24BAAB1B-84BA-409A-B2DF-F3E33455C029

Q39508981-24C6678B-C061-4D5C-AB71-160AA7757CDA

Q39508981-2A9801B0-C0D7-4014-AC68-CEF202B6053F

Q39508981-32A778C7-2C1C-47DA-8453-47435AC4B783

Q39508981-33A283B9-2BD2-482E-82BD-25AF24FC7968

Q39508981-48036C09-13E7-4240-ABF7-BD42F8756826

Q39508981-49828D4E-75E3-4162-AFB0-295801FD0B69

P304

Q39508981-A0C84D11-0CF1-43CE-8E13-BAA41ED67A3E

P31

Q39508981-5AAE0640-760A-42ED-B4CC-B39C9CCC64AD

P356

Q39508981-168D9A0C-DD1D-4D92-B54B-AD8F5923EA44

P433

Q39508981-96BA1167-26FD-410B-8DFD-3A55189E9A0E

P478

Q39508981-936454C2-6C26-41AD-AB24-E2E479FDF0AC

P50

Q39508981-03273950-EBE7-49B5-9401-D89287A1410F

Q39508981-60E63E74-6C4A-49A9-8EF9-52A88DB4FB0A

P577

Q39508981-30590C91-431D-4C1A-95FA-FD34CD62A685

P5875

Q39508981-AF7C9316-C781-4C90-8B74-EBFB20933931

P698

Q39508981-FFE7F3F3-BD9B-4E73-A3FE-2EF2D6F4053F

P921

Q39508981-EE7799C0-E07D-4DC4-9B71-D6B5911C2B97

P932

Q39508981-0BED09CF-BB9F-4D96-91B1-91A4D7594469

P356

P1433

Molecular Therapy

P1476

The effect of chemical modific ...... odistribution of siRNA in mice

@en

P2093

Ebbe Juel Bech Nielsen

http://www.w3.org/2001/XMLSchema#string

Flemming Besenbacher

http://www.w3.org/2001/XMLSchema#string

Frederik Dagnaes-Hansen

http://www.w3.org/2001/XMLSchema#string

Kenneth Alan Howard

http://www.w3.org/2001/XMLSchema#string

Shan Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality

Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model.

Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.

Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung.

Key issues in non-viral gene delivery.

siRNAs: applications in functional genomics and potential as therapeutics.

RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

RNA interference and chemically modified small interfering RNAs.

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

P304

1225-1233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.91

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24376572

http://www.w3.org/2001/XMLSchema#string

P698

19401674

http://www.w3.org/2001/XMLSchema#string

P921

P932

2835214

http://www.w3.org/2001/XMLSchema#string